Featured Research

from universities, journals, and other organizations

Promising Approach In Prevention And Treatment Of Pancreatic Cancer

Date:
September 29, 2008
Source:
World Journal of Gastroenterology
Summary:
Pancreatic cancer is one of the most lethal human cancers and continues to be a major unsolved health problem. The overexpression of the epidermal growth factor receptor and its ligands correlates with rapidly progressive disease and resistance to chemotherapy.

Pancreatic cancer is one of the most lethal human cancers and continues to be a major unsolved health problem. The overexpression of the epidermal growth factor receptor and its ligands correlates with rapidly progressive disease and resistance to chemotherapy.

Related Articles


This study investigated the growth inhibitory effects of erlotinib in pancreatic cancer cells in vitro and in vivo.

Many gastrointestinal tumors, including pancreatic cancer, have been shown to overexpress the EGFR. The overexpression of EGFR correlates with rapidly progressive disease and poor prognosis. Targeting EGFR pathway as a potential therapeutic strategy for pancreatic cancer has been developed. Erlotinib is a small molecule tyrosine kinase inhibitor that efficiently blocks EGFR. Preliminary results of phase III trial in pancreatic cancer revealed an improvement in survival with the addition of erlotinib. Treatment with anti-EGFR agents is used as a potential therapeutic strategy for pancreatic cancer, but the mechanisms are not yet precisely understood.

The research team from Department of Gastroenterology, Affiliated First People's Hospital, Shanghai Jiao Tong University, China studied the effects of erlotinib on six different pancreatic cancer cell lines. How erlotinib exhibits its antineoplastic activity in vivo needs to be further elucidated.

In this study authors revealed the efficacy of erlotinib, as a single agent, on pancreatic cancer cells growth in vitro, and in vivo study using a nude mice xenograft model and the mechanisms involved were also explored. Erlotinib repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis,and suppressed capillary formation of endothelium in vitro.

In vivo, erlotinib treated mice demonstrated a reduced tumor volume and weight as compared with control. The relationship between EGFR and angiogenesis has also been investigated using tube formation assay in vitro and immunohistochemical analysis of tumor-associated blood vessels in vivo. These findings provide evidence for the inhibitive activity of erlotinib in pancreatic cancer cells. Inhibition of EGFR may be a promising adjuvant in chemotherapeutic strategy in the treatment of the dismal disease. The results also demonstrate that EGFR signaling pathway is an important target in pancreatic cancer.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Lu et al. Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line. World Journal of Gastroenterology, September 21, 2008; 14 (35): 5403 DOI: 10.3748/wjg.14.5403

Cite This Page:

World Journal of Gastroenterology. "Promising Approach In Prevention And Treatment Of Pancreatic Cancer." ScienceDaily. ScienceDaily, 29 September 2008. <www.sciencedaily.com/releases/2008/09/080925094715.htm>.
World Journal of Gastroenterology. (2008, September 29). Promising Approach In Prevention And Treatment Of Pancreatic Cancer. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2008/09/080925094715.htm
World Journal of Gastroenterology. "Promising Approach In Prevention And Treatment Of Pancreatic Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/09/080925094715.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins